Clinical trial
Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma: a Prospective, Double-blind, Multicenter, Randomized Controlled Phase II Trial
NCT06703047 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma: a Prospective, Double-blind, Multicenter, Randomized Controlled Phase II Trial
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 20, 2024
- Completion date
- October 24, 2030
- Enrollment
- 180 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.